Immunogenicity of induced pluripotent stem cells.

By K. Okita, N. Nagata, S. Yamanaka. Circulation Research, 2011

884 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Production of De Novo Cardiomyocytes: Human Pluripotent Stem Cell Differentiation and Direct Reprogramming (2012, background): “In addition, concerns over cell survival, immune rejection, electrical maturation, electrical coupling, arrhythmia, and whether autologous hiPSCs possess immune privileges (a question that has recently been raised with murine iPSCs; Zhao et al., 2011) still need to be addressed.”
Emerging trends and new developments in regenerative medicine: a scientometric update (2000 – 2014) (2014, background): “…2011 2014 8 Polo et al. (2010) NAT BIOTECHNOL, V28, P848 [48] 65.3 2011 2014 9 Hanahan and Weinberg (2011) CELL, V144, P646 [31] 93.1 2012 2014 10 Zhao et al. (2011) NATURE, V474, P212 [16] 78.9 2012 2014 11 Anokye-Danso et al. (2011) CELL STEM CELL, V8, P376 [33] 78.7 2012 2014 12 Dasha et al.…”
Energy Metabolism in Human Pluripotent Stem Cells and Their Differentiated Counterparts (2011, background): “[14] demonstrated immunogenicity differences between authentic ESCs and iPSCs.”